Micah Olson
Pediatric Endocrinology · Phoenix, AZNPI 1417981440
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,370 of the $9,422 with a category attached, or 78.2%. Rhythm Pharmaceuticals, Inc. accounts for 85.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2022 at $5,421 and has fallen 99.7% since, to $18 in 2025.
Across 92 payments — averaging $102.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rhythm Pharmaceuticals, Inc.$8K
- Pfizer$284
- Novo Nordisk$167
- Medtronic$140
- Ultragenyx Pharmaceutical Inc.$121
- Insulet Corporation$91
- plus $611 from 19 others
Across 74 payments — averaging $3794.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$176K
- Rhythm Pharmaceuticals, Inc.$49K
- Boehringer Ingelheim Pharma GmbH & Co.kg$35K
- Merck$17K
- Boehringer Ingelheim France S.a.s.$4K
What the payments were for
- Speaking & faculty fees$7,37078%
- Travel & lodging$3574%
- Food & beverage$1,69418%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. | 13 | $8,008 |
| Pfizer | 17 | $284 |
| Novo Nordisk | 11 | $167 |
| Medtronic(2 entities) | 7 | $140 |
| Ultragenyx Pharmaceutical Inc. | 5 | $121 |
| Insulet Corporation | 6 | $91 |
| AbbVie | 4 | $63 |
| Tolmar Pharmaceuticals, Inc. | 3 | $60 |
| Arbor Pharmaceuticals, Inc. | 3 | $59 |
| Abbott | 3 | $48 |
| Intuity Medical Inc | 2 | $45 |
| Lilly USA, LLC | 3 | $43 |
| Dexcom, Inc. | 2 | $40 |
| Ipsen Biopharmaceuticals, Inc | 2 | $37 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Lifescan, Inc. | 1 | $23 |
| Bayer | 1 | $22 |
| Zealand Pharma US, Inc. | 1 | $19 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Tandem Diabetes Care, Inc. | 1 | $17 |
| Companion Medical, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Imcivree$7,977
How this compares
$9,422 in reported general payments places this provider in the 85th percentile of 35 pediatric endocrinology providers in Arizona.
Other pediatric endocrinology in Phoenix
- Eileen Baez IrizarryPhoenix$53K
- Pamela SmithPhoenix$26K
- Chirag KapadiaPhoenix$13K
- Grazyna Piekos-SobczakPhoenix$12K
- Rola SaadPhoenix$10K
- Rochelle WilsonPhoenix$4K
- Amanda CamposPhoenix$3K
- Mahmoud KabbaniPhoenix$3K
- Melissa ChambersPhoenix$3K
- Dorothee NewbernPhoenix$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.